lncRNA HULC在弥漫性大B细胞淋巴瘤患者中表达及其临床意义

Expression and clinical significance of lncRNA HULC in diffuse large B-cell lymphoma

目的探讨lncRNA HULC在弥漫性大B细胞淋巴瘤患者中的表达情况,及其与临床病理特征、预后的关系。方法 154例弥漫性大B细胞淋巴瘤患者(淋巴瘤组),取其淋巴瘤组织;32例淋巴结反应性增生患者(对照组),取其淋巴结反应性增生组织。采用实时荧光定量PCR法检测2组组织中lncRNA HULC相对表达量。以lncRNA HULC相对表达量中位数(2.09)将淋巴瘤组患者分为低表达组(lncRNA HULC相对表达量<2.09)和高表达组(lncRNA HULC相对表达量≥2.09),分析lncRNA HULC相对表达量与临床病理特征的关系;采用Kaplan-Meier法绘制生存曲线,分析弥漫性大B细胞淋巴瘤患者lncRNA HULC表达水平对临床预后的影响;采用Cox比例风险回归模型分析弥漫性大B细胞淋巴瘤患者预后不良的危险因素。结果淋巴瘤组组织中lncRNA HULC相对表达量(4.17±0.02)明显高于对照组(1.04±0.03)(P<0.05);高表达组肿瘤直径>5cm(61.04%)、有B症状(64.94%)、淋巴瘤国际预后指数3～5(64.94%)、化疗不敏感(64.94%)、TNM分期Ⅲ～Ⅳ期(64.94%)比率高于低表达组(48.05%、40.26%、45.45%、49.35%、51.95%)(P<0.05),高表达组患者总体存活率(33.77%)和总生存时间[(481±35)d]低于低表达组[58.44%、(913±51)d)](P<0.05);lncRNA HULC高表达为弥漫性大B细胞淋巴瘤患者预后不良的独立危险因素(HR=3.298,95%CI:1.531～5.515,P=0.006)。结论 lncRNA HULC高表达与弥漫性大B细胞淋巴瘤预后不良相关;lncRNAHULC可作为预测弥漫性大B细胞淋巴瘤患者预后的潜在生物标志物。

Objective To investigate the expression of long non-coding RNA(lncRNA)HULC in patients with diffuse large B-cell lymphoma(DLBCL)and its correlation with the clinicopathological features and prognosis of DLBCL.Methods The expression levels of lncRNA HULC were detected in the DLBCL tissues in 154 patients with DLBCL(DLBCL group)and the lymph node reactive hyperplasia tissues in 32 patients with reactive hyperplasis(control group)by real-time PCR technique.DLBCL group was redivided into low expression group(lncRNA HULC<2.09)and high expression group(lncRNA HULC ≥2.09)according to the median of relative lncRNA HULC expression.The relationship between lncRNA HULC relative expression and clinicopathological features was analyzed.Kaplan-Meier method was used to analyze the influence of lncRNA HULC on the prognosis of DLBCL.Cox proportional hazards regression model was used to analyze the risk factors for poor prognosis of DLBCL patients.Results The relative expression of lncRNA HULC was significantly higher in DLBCL group(4.17±0.02)than that in control group(1.04±0.03)(P<0.05).The percentages of tumor diameter >5 cm(61.04%),B symptoms(64.94%),International Prognostic Index score 3-5(64.94%),chemotherapy tolerance(64.94%)and TNM stage Ⅲ-Ⅳ(64.94%)in high expression group were significantly higher than those in low expression group(48.05%,40.26%,45.45%,49.35%,51.95%)(P<0.05).The overall survival rate was significantly lower in high expression group(33.77%)than that in low expression group(58.44%)(P<0.05),and the overall survival time was significantly shorter in high expression group((481±35)d)than that in low expression group((913±51)d)(P<0.05).The increased level of lncRNA HULC was a risk factor for DLBCL(HR=3.298,95%CI:1.531-5.515,P=0.006).Conclusion The high expression of lncRNA HULC is correlated with the poor prognosis of DLBCL,and lncRNA HULC might serve as a promising biomarker for predicting the prognosis of DLBCL.